BEAM (Beam Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

BEAM (Beam Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

BEAMBeam Therapeutics Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$140M

Net Income (TTM)-$80M

EPS (TTM)-$1.01

Free Cash Flow (TTM)-$360M

Gross Margin-126.1%

Op. Margin-274.6%

Net Margin-57.2%

FCF Margin-257.7%

P/S Ratio (TTM)20.0x

P/E Ratio (TTM)—

YoY Rev Growth+120.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$24M	-$75M	-$99M
Q2 23	$20M	-$77M	-$102M
Q3 23	$17M	-$83M	-$108M
Q4 23	$316M	$176M	$133M
Q1 24	$7M	-$77M	-$104M
Q2 24	$12M	$12M	-$105M
Q3 24	$14M	-$80M	-$107M
Q4 24	$30M	-$71M	-$100M
Q1 25	$7M	-$91M	-$119M
Q2 25	$8M	-$93M	-$120M
Q3 25	$10M	-$100M	-$127M
Q4 25	$114M	$108M	-$17M

Valuation

Quarter	P/S	P/E
Q1 23	36.4x	—
Q2 23	34.8x	—
Q3 23	34.2x	—
Q4 23	7.4x	—
Q1 24	7.7x	—
Q2 24	7.9x	—
Q3 24	8.0x	—
Q4 24	43.9x	—
Q1 25	43.9x	—
Q2 25	46.3x	—
Q3 25	50.1x	—
Q4 25	20.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$110M	-$116M
Q2 23	-$85M	-$101M
Q3 23	-$90M	-$98M
Q4 23	$135M	$131M
Q1 24	-$100M	-$102M
Q2 24	-$83M	-$85M
Q3 24	-$88M	-$90M
Q4 24	-$76M	-$79M
Q1 25	-$104M	-$107M
Q2 25	-$76M	-$80M
Q3 25	-$81M	-$86M
Q4 25	-$83M	-$87M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$6M
Q2 23	$16M
Q3 23	$8M
Q4 23	$4M
Q1 24	$2M
Q2 24	$2M
Q3 24	$2M
Q4 24	$3M
Q1 25	$3M
Q2 25	$3M
Q3 25	$5M
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+187.1%	+45.5%
Q2 23	+20.8%	+24.0%
Q3 23	+8.8%	+17.1%
Q4 23	+1478.0%	+68.2%
Q1 24	-69.4%	-9.4%
Q2 24	-41.5%	-4.6%
Q3 24	-17.0%	-3.7%
Q4 24	-90.5%	-29.0%
Q1 25	+0.8%	+13.6%
Q2 25	-28.1%	+10.2%
Q3 25	-32.0%	+13.0%
Q4 25	+279.5%	+1.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$24M	98.8%
Q2 23	$26M	130.6%
Q3 23	$26M	150.3%
Q4 23	$23M	7.2%
Q1 24	$29M	395.2%
Q2 24	$32M	268.5%
Q3 24	$30M	207.2%
Q4 24	$30M	100.5%
Q1 25	$27M	357.2%
Q2 25	$24M	287.8%
Q3 25	$23M	234.6%
Q4 25	-$74M	-64.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$100M	$23M
Q2 23	$98M	$25M
Q3 23	$100M	$25M
Q4 23	$140M	$43M
Q1 24	$85M	$27M
Q2 24	$87M	$30M
Q3 24	$94M	$27M
Q4 24	$101M	$29M
Q1 25	$99M	$28M
Q2 25	$102M	$27M
Q3 25	$110M	$27M
Q4 25	$99M	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$250M	$810M	$1.1B
Q2 23	$226M	$847M	$1.1B
Q3 23	$169M	$846M	$1.0B
Q4 23	$436M	$754M	$1.2B
Q1 24	$288M	$807M	$1.1B
Q2 24	$293M	$715M	$1.0B
Q3 24	$230M	$696M	$926M
Q4 24	$282M	$569M	$851M
Q1 25	$528M	$692M	$1.2B
Q2 25	$282M	$868M	$1.2B
Q3 25	$268M	$807M	$1.1B
Q4 25	$295M	$950M	$1.2B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	72M	+2.1%
Q2 23	76M	+5.6%
Q3 23	79M	+3.5%
Q4 23	83M	+4.7%
Q1 24	82M	-1.2%
Q2 24	82M	+0.8%
Q3 24	82M	+0.1%
Q4 24	83M	+0.5%
Q1 25	88M	+6.2%
Q2 25	102M	+15.9%
Q3 25	103M	+0.6%
Q4 25	105M	+2.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	$153	118
FY 20	$133	181
FY 21	$864	60K
FY 22	$1K	60K
FY 23	$4K	100K
FY 24	$635	100K
FY 25	$1K	100K